Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

Hospital-acquired infections at an oncological intensive care cancer unit: differences between solid and hematological cancer patients

Authors: Patricia Cornejo-Juárez, Diana Vilar-Compte, Alejandro García-Horton, Marco López-Velázquez, Silvio Ñamendys-Silva, Patricia Volkow-Fernández

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

Cancer patients have a higher risk of severe sepsis in comparison with non-cancer patients, with an increased risk for hospital-acquired infections (HAI), particularly with multidrug resistant bacteria (MDRB). The aim of the study is to describe the frequency and characteristics of HAI and MDRB in critically ill cancer patients.

Methods

We conducted an 18-month prospective study in patients admitted ≥48 h to an ICU at a cancer referral center in Mexico. Patients with hematological malignancies (HM) were compared with solid tumors. Demographic and clinical data were recorded. Mortality was evaluated at 30-days.

Results

There were 351 admissions during the study period, among whom 157 (66 %) met the inclusion criteria of the study as follows: 104 patients with solid tumors and 53 with HM. Sixty-four patients (40.7 %) developed 95 episodes of HAI. HAI rate was 4.6/100 patients-days. MDRB were isolated in 38 patients (24 %), with no differences between both groups. Escherichia coli was the main bacteria isolated (n = 24), 78 % were extended spectrum beta-lactamases producers. The only risk factor associated with HAI was the presence of mechanical ventilation for more than 5 days (OR 3.12, 95 % CI 1.6 – 6.2, p = 0.001). At 30-day follow-up, 61 patients (39 %) have died (38 % with solid tumors and 60 % with HM, p < 0.001). No differences were found in mortality at 30-day between patients with HAI (n = 25, 39 %) vs. non-HAI (n = 36, 38.7 %, p = 0.964); neither in those who developed a HAI with MDRB (n = 12, 35.3 %) vs. HAI with non-MDRB (n = 13, 43.3 %, p = 0.51).

Conclusions

Patients with cancer who are admitted to an ICU, have a high risk of HAI, but there were no differences patients with solid or hematologic malignancies.
Literature
1.
go back to reference Vitrat V, Hautefeuille S, Janssen C, Bougon D, Sirodot M, Pagani L. Optimizing antimicrobial therapy in critically ill patients. Infect Drug Resist. 2014;7:261–71.PubMedPubMedCentral Vitrat V, Hautefeuille S, Janssen C, Bougon D, Sirodot M, Pagani L. Optimizing antimicrobial therapy in critically ill patients. Infect Drug Resist. 2014;7:261–71.PubMedPubMedCentral
2.
go back to reference Textoris J, Wiramus S, Martin C, Leone M. Overview of antimicrobial therapy in intensive care units. Expert Rev Anti Infect Ther. 2011;9:97–109.CrossRefPubMed Textoris J, Wiramus S, Martin C, Leone M. Overview of antimicrobial therapy in intensive care units. Expert Rev Anti Infect Ther. 2011;9:97–109.CrossRefPubMed
4.
go back to reference Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. EPIC II Group of Investigators International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–9. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. EPIC II Group of Investigators International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–9.
5.
go back to reference Aly NY, Al-Mousa HH, el Al Asar SM. Nosocomial infections in a medical-surgical intensive care unit. Med Princ Pract. 2008;17:373–7.CrossRefPubMed Aly NY, Al-Mousa HH, el Al Asar SM. Nosocomial infections in a medical-surgical intensive care unit. Med Princ Pract. 2008;17:373–7.CrossRefPubMed
6.
go back to reference Montassier E, Batard E, Gastinne T, Potel G, de la Cochetière MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32:841–50.CrossRefPubMed Montassier E, Batard E, Gastinne T, Potel G, de la Cochetière MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32:841–50.CrossRefPubMed
7.
go back to reference Neidell NJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;55:807–15.CrossRefPubMedPubMedCentral Neidell NJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;55:807–15.CrossRefPubMedPubMedCentral
8.
go back to reference Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2011;134:298–314.CrossRef Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2011;134:298–314.CrossRef
9.
go back to reference Kostakou E, Rovina N, Kyriakopoulou M, Koulouris NG, Koutsoukou A. Critically ill cancer patient in intensive care unti: issues that arise. J Crit Care. 2014;29:817–22.CrossRefPubMed Kostakou E, Rovina N, Kyriakopoulou M, Koulouris NG, Koutsoukou A. Critically ill cancer patient in intensive care unti: issues that arise. J Crit Care. 2014;29:817–22.CrossRefPubMed
10.
go back to reference Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing. Approved Standard M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013. Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing. Approved Standard M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
11.
go back to reference Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CE, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.CrossRefPubMed Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CE, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.CrossRefPubMed
13.
go back to reference Ariza-Heredia EJ, Chemaly RF. Infection control practices in patients with hematological malignancies and multidrug-resistant organisms: special considerations and challenges. Cl Lymph Myelom Leuk. 2014;14(Suppl):104–10.CrossRef Ariza-Heredia EJ, Chemaly RF. Infection control practices in patients with hematological malignancies and multidrug-resistant organisms: special considerations and challenges. Cl Lymph Myelom Leuk. 2014;14(Suppl):104–10.CrossRef
14.
go back to reference Namendys-Silva SA, Texcocano-Becerra J, Herrera-Gómez A. Prognostic factors in critically ill patients with solid tumours admitted to an oncological intensive care unit. Anaesth Intensive Care. 2010;38:317–24.PubMed Namendys-Silva SA, Texcocano-Becerra J, Herrera-Gómez A. Prognostic factors in critically ill patients with solid tumours admitted to an oncological intensive care unit. Anaesth Intensive Care. 2010;38:317–24.PubMed
15.
go back to reference Unseld S, Schuepbach RA, Maggiorini M. ICU, hospital and one year mortality of patients suffering from solid or haematological malignancies. Swiss Med Wkly. 2013;143:w13741. doi:10.4414/smw.2013.13741.PubMed Unseld S, Schuepbach RA, Maggiorini M. ICU, hospital and one year mortality of patients suffering from solid or haematological malignancies. Swiss Med Wkly. 2013;143:w13741. doi:10.​4414/​smw.​2013.​13741.PubMed
16.
go back to reference Song JU, Suh GY, Chung MP, Kim H, Kwon OJ, Jung CW, Kang WK, Park K, Jeon K. Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. Support Care Cancer. 2011;19:491–5.CrossRefPubMed Song JU, Suh GY, Chung MP, Kim H, Kwon OJ, Jung CW, Kang WK, Park K, Jeon K. Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. Support Care Cancer. 2011;19:491–5.CrossRefPubMed
17.
go back to reference Aygencel G, Turkoglu M, Turkoz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014;29:618–26.CrossRefPubMed Aygencel G, Turkoglu M, Turkoz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014;29:618–26.CrossRefPubMed
18.
go back to reference Sammon J, Trinh VQ, Ravi P, Sukumar S, Gervais MK, Shariat SF, et al. Health care-associated infections after major cancer surgery: temporal trends, patterns of care, and effect on mortality. Cancer. 2013;119:2317–24.CrossRefPubMed Sammon J, Trinh VQ, Ravi P, Sukumar S, Gervais MK, Shariat SF, et al. Health care-associated infections after major cancer surgery: temporal trends, patterns of care, and effect on mortality. Cancer. 2013;119:2317–24.CrossRefPubMed
19.
go back to reference Dereli N, Ozayar E, Degerli S, Sahin S, Koç F. Three-year evaluation of nosocomial infection rates of the ICU. Rev Bras Anesthesiol. 2013;63:73–84.CrossRef Dereli N, Ozayar E, Degerli S, Sahin S, Koç F. Three-year evaluation of nosocomial infection rates of the ICU. Rev Bras Anesthesiol. 2013;63:73–84.CrossRef
20.
go back to reference Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med. 2006;145:582–91.CrossRefPubMed Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med. 2006;145:582–91.CrossRefPubMed
21.
go back to reference Coffin SE, Komplas M, Classen D, Arias KM, Podgorny K, Anderson DJ, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29 Suppl 31:31–40. Coffin SE, Komplas M, Classen D, Arias KM, Podgorny K, Anderson DJ, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29 Suppl 31:31–40.
22.
go back to reference Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008;29:996–1011.CrossRefPubMed Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008;29:996–1011.CrossRefPubMed
23.
go back to reference Wagenlehner FM, Weidner W, Naber KG. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamics considerations. J Hosp Infect. 2005;60:191–200.CrossRefPubMed Wagenlehner FM, Weidner W, Naber KG. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamics considerations. J Hosp Infect. 2005;60:191–200.CrossRefPubMed
24.
go back to reference DiGiorgio MJ, Fatica C, Oden M, Bolwell B, Sekeres M, Kalaycio M, et al. Development of a modified surveillance definition of central line-associated bloodstream infections for patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2012;33:865–8.CrossRefPubMed DiGiorgio MJ, Fatica C, Oden M, Bolwell B, Sekeres M, Kalaycio M, et al. Development of a modified surveillance definition of central line-associated bloodstream infections for patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2012;33:865–8.CrossRefPubMed
25.
go back to reference Volkow P, Sanchez-Mejorada G, de la Vega SL, Vazquez C, Tellez O, Baez RM, et al. Experience of an intravenous therapy team at the Instituto Nacional de Cancerologia (mexico) with a long-lasting, low-cost silastic venous catheter. Clin Infect Dis. 1994;18:719–25.CrossRefPubMed Volkow P, Sanchez-Mejorada G, de la Vega SL, Vazquez C, Tellez O, Baez RM, et al. Experience of an intravenous therapy team at the Instituto Nacional de Cancerologia (mexico) with a long-lasting, low-cost silastic venous catheter. Clin Infect Dis. 1994;18:719–25.CrossRefPubMed
26.
go back to reference Volkow P, Vázquez C, Téllez O, Aguilar C, Barrera L, Rodríguez E, et al. Polyurethane II catheter as long-indwelling intravenous catheter in patients with cancer. Am J Infect Control. 2003;31:392–6.CrossRefPubMed Volkow P, Vázquez C, Téllez O, Aguilar C, Barrera L, Rodríguez E, et al. Polyurethane II catheter as long-indwelling intravenous catheter in patients with cancer. Am J Infect Control. 2003;31:392–6.CrossRefPubMed
27.
go back to reference Morfin-Otero R, Noriega ER, Dowzicky MJ. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial. Ann Clin Microbiol Antimicrob. 2015;14:53. doi:10.1186/s12941-015-0116-y.CrossRefPubMedPubMedCentral Morfin-Otero R, Noriega ER, Dowzicky MJ. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial. Ann Clin Microbiol Antimicrob. 2015;14:53. doi:10.​1186/​s12941-015-0116-y.CrossRefPubMedPubMedCentral
28.
go back to reference Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010). Diagn Microbiol Infect Dis. 2012;73:354–60.CrossRefPubMed Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010). Diagn Microbiol Infect Dis. 2012;73:354–60.CrossRefPubMed
29.
go back to reference Morfin-Otero R, Tinoco-Favila JC, Sader HS, Salcido-Gutierrez L, Perez-Gomez HR, Gonzalez-Diaz E, Petersen L, Rodriguez-Noriega E. Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005–2010. BMC Res Notes. 2012;5:277. doi:10.1186/1756-0500-5-277.CrossRefPubMedPubMedCentral Morfin-Otero R, Tinoco-Favila JC, Sader HS, Salcido-Gutierrez L, Perez-Gomez HR, Gonzalez-Diaz E, Petersen L, Rodriguez-Noriega E. Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005–2010. BMC Res Notes. 2012;5:277. doi:10.​1186/​1756-0500-5-277.CrossRefPubMedPubMedCentral
30.
go back to reference Schwaber MJ, Carmeli Y. The effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy. (Abstract). Crit Care. 2009; doi: 10.1186/cc7136. Epub 2009 Jan 12. Schwaber MJ, Carmeli Y. The effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy. (Abstract). Crit Care. 2009; doi: 10.​1186/​cc7136. Epub 2009 Jan 12.
31.
go back to reference Cornejo-Juárez P, Vilar-Compte D, Pérez-Jiménez C, Ñamendys-Silva SA, Sandoval-Hernández S, Volkow-Fernández P. The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int J Infec Dis. 2015;31:31–4.CrossRef Cornejo-Juárez P, Vilar-Compte D, Pérez-Jiménez C, Ñamendys-Silva SA, Sandoval-Hernández S, Volkow-Fernández P. The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int J Infec Dis. 2015;31:31–4.CrossRef
32.
go back to reference Llaca-Díaz JM, Mendoza-Olazarán S, Camacho-Ortiz A, Flores S, Garza-González E. One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey Mexico. Chemotherapy. 2012;58:475–81.CrossRefPubMed Llaca-Díaz JM, Mendoza-Olazarán S, Camacho-Ortiz A, Flores S, Garza-González E. One-year surveillance of ESKAPE pathogens in an intensive care unit of Monterrey Mexico. Chemotherapy. 2012;58:475–81.CrossRefPubMed
Metadata
Title
Hospital-acquired infections at an oncological intensive care cancer unit: differences between solid and hematological cancer patients
Authors
Patricia Cornejo-Juárez
Diana Vilar-Compte
Alejandro García-Horton
Marco López-Velázquez
Silvio Ñamendys-Silva
Patricia Volkow-Fernández
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1592-1

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue